NCT07509632Active, not recruiting
Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning
Development and Validation of a Machine Learning Model Based on Clinical and MRI Features for Predicting Pathological Complete Response in Rectal Cancer Following Neoadjuvant Chemoradiotherapy
Source: ClinicalTrials.gov · Last updated 3 Apr 2026
Brief summary (registry, in English)
This study aims to develop and validate a robust machine learning-based prediction model utilizing baseline clinical data and magnetic resonance imaging (MRI) features. The objective is to preoperatively predict the probability of achieving a pathological complete response (pCR) in patients with locally advanced rectal cancer (CRC) following neoadjuvant chemoradiotherapy (nCRT).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 320 (estimated)
- First submitted
- 29 Mar 2026
- Start date
- 4 Feb 2026
- Primary completion date
- 25 Apr 2026
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT07509632
What you commit to
- Study type: Observational
- Planned participants: 320
- From 4 Feb 2026 to the primary completion date, 25 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Underwent emergency surgery during nCRT;
Other illness
- Previous history of other malignant tumors;
- Complicated with systemic infection or hematological diseases.
Other
- Incomplete clinical data;
Who the study is looking for
- Patients with histopathologically confirmed rectal adenocarcinoma;
- Clinical stage cT3-4, or cN+, or M1 advanced rectal cancer;
- Received standardized neoadjuvant chemoradiotherapy or neoadjuvant chemotherapy;
- Underwent total mesorectal excision (TME) after the completion of neoadjuvant therapy, with complete postoperative pathological data available.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.